A Combination Efficacy Study in Africa of Two DNA-MVA-Env Protein or DNA-Env Protein HIV-1 Vaccine Regimens With PrEP
Condition: HIV Infections Interventions: Biological: Vaccine Group A: DNA-HIV-PT123 and AIDSVAX® B/E (weeks 0,4,24,48); Biological: Vaccine Group B: DNA-HIV-PT123 and CN54gp140+MPLA-L (weeks 0,4), then MVA and CN54gp140+MPLA-L (weeks 24,48); Biological: Vaccine Group C: Saline placebo (weeks 0,4,24,48); Drug: Control PrEP:TDF /FTC once daily (weeks 0-26); Drug: Experimental PrEP:TAF/FTC once daily (weeks 0-26) Sponsors: MRC/UVRI Uganda Research Unit on Aids; Imperial College London; University College, London; International AIDS Vaccine Initiative; EuroVacc Foundation; Medical Research Council, South Africa; National Institute for Medical Research, Tanzania; Muhimbili University of Health and Allied Sciences; Instituto Nacional de Saúde, Mozambique; Ludwig-Maximilians - University of Munich; King's College London; Centre Hospitalier Universitaire Vaudois; Karolinska Institutet; CONRAD; Gilead Sciences Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
More News: African Health | AIDS Vaccine | HIV AIDS | Mozambique Health | Research | Study | Tanzania Health | Vaccines